Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-11-07
2006-11-07
Wax, Robert A. (Department: 1653)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C514S012200, C530S300000
Reexamination Certificate
active
07132246
ABSTRACT:
Use of novel soluble cytokeratin 1 fragments from body fluids or body tissues as marker peptides for the diagnosis, prognosis and monitoring of the course of inflammations and infections and/or as a target for the therapeutic influencing of the course of inflammations and/or infections.
REFERENCES:
patent: 5527773 (1996-06-01), Steinert et al.
patent: 5639617 (1997-06-01), Bohuon
patent: 5660994 (1997-08-01), Bruder-Heid et al.
patent: 6190872 (2001-02-01), Slotman
patent: 198 47 690 (2000-04-01), None
patent: 0 163 304 (1985-12-01), None
patent: 0 267 356 (1991-01-01), None
patent: 0 267 355 (1991-09-01), None
patent: 0 337 057 (1993-04-01), None
patent: 0 656 121 (1998-03-01), None
patent: WO 97 25622 (1997-07-01), None
patent: WO 00/22439 (2000-04-01), None
patent: WO 01/12212 (2001-02-01), None
Hotchkiss, R. and Karl,I. N Eng J Med 348:2 138-150 (2003).
Aird, W. Mayo Clin Proc. 78: 869-881 (2003).
Carrigan, S. et al. Clinical Chemistry 50:8 1301-1314 (2004).
NCBI FASTA protein sequence of keratin I Dec. 10, 1999.
NCBI FASTA protein sequence of interleukin-6 Aug. 6, 2006.
Assicot, et al., “High Serum Procalcitonin Concentrations in Patients with Sepsis and Infection,”Lancet, 341(8844):515-518, 1993.
Beishuizen et al., “Endogenous Mediators in Sepsis and Septic Shock,”Advances Clin. Chem., 363:55-131, 1999.
Calandra et al., “Protection from Septic Shock by Neutralization of Macrophage Migration Inhibitory Factor,”Nature Medicine, 6(2):164-170, 2000.
Gabay and Kushner, “Acute-Phase Proteins and Other Systemic Responses to Inflammation,”New Engl. J. Med., 340(6):448-454, 1999.
Garber, “Protein C May Be Sepsis Solution,”Nature Biotechnology, 18:917-918, 2000.
Ghillani et al., “Monoclonal Antipeptide as Tools to Dissect Closely Related Gene Products,”J. Immunol., 141(9):3156-3163, 1988.
Ghillani et al., “Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases,”Cancer Research, 49(23):6845-6851, 1989.
Heukeshoven and Dernick, “Improved Silver Staining Procedure for Fast Staining in PhastSystem Development Unit. I. Staining of Sodium Dodecyl Sulfate Gels,”Electrophoresis, 9(1):28-32, 1988.
Joseph et al., “Factor XII-Dependent Contact Activation on Endothelial cells and Binding Proteins gClqR and Cytokeratin 1,”Throm. Haemost., 85:119-124, 2001.
Joseph et al., “Activation of the Kinin-Forming Cascade on the Surface of Endothelial Cells,”Biol. Chem., 382:71-75, 2001.
Kanazawa et al., “CYFRA 21-1, A Cytokeratin Subunit 19 Fragment, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease,”Clin. Sci., 94:531-535, 1998.
Kaplan et al., “Activation of the Plasma Kinin Forming Cascade Along Cell Surfaces,”Int. Arch. Allergy Immunol., 124:339-341, 2001.
Karzai, et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections,”Infections, 25:3-8, 1997.
Klose, “Fractionated Extraction of Total Tissue Proteins from Mouse and Human for 2-D Electrophoresis,”In: Methods in Molecular Biology, vol. 112, 2-D Proteame Analysis Protocols, Humana Press Inc., N.J., pp. 67-85.
Klose and Kobalz, “Two-Dimensional Electrophoresis of Proteins: An Updated Protocol and Implications for a Functional Analysis of the Genome,”Electrophoresis, 16:1034-1059, 1995.
Lamerdin et al., EMBL Database Accession No. 075272.
Lingner et al., “Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase,”Science, 276:561-567, 1997.
Lucas et al., “Aberrantly Expressed Cytokeratin 1, A Tumor-Associated Autoantigen in Papillary Thyroid Carcinoma,”Int. J. Cancer, 73:171-177, 1997.
Lucas et al., “Identification of a 35 kD Tumor-Associated Autoantigen in Papillary Thyroid Carcinoma,”Anticancer Research, 16:2493-2496, 1996.
Mann and Pandey, “Use of Mass Spectrometry-Derived Data to Annotate Nucleotide and Protein Sequence Databases,”TRENDS Biochem. Sci., 26(1):54-61, 2001.
Neubauer et al., Mass Spectrometry and EST-Database Searching Allows Characterization of the Multi-Protein Spliceosome Complex,Nature Genetics, 20:46-50, 1998.
Neuhoff et al., “Improved Staining of Proteins in Polyacrylamide Gels Including Isoelectric Focusing Gels with Clear Background at Nanogram Sensitivity Using Coomassie Brilliant Blue G-250 and R-250,”Electrophoresis, 9:255-262, 1988.
Oczenski et al., “Procalcitonin: A New Parameter for the Diagnosis of Bacterial Infection in the Peri-Operative Period,”Eur. J. Anaesthesiol., 15:202-209, 1998.
Omary et al., “Keratin Modifications and Solubility Properties in Epithelial Cells andIn vitro,” Subcellular Biochemistry, 31:105-140, 1998.
Otto et al., “Identification of Human Myocardial Proteins Separated by Two-Dimensional Electrophoresis Using an Effective Sample Preparation for Mass Spectrometry,”Electrophoresis, 17:1643-1650, 1996.
Panacek, “Anti-TNF Strategies,”Intensive Care Med., 23:1144-1149, 1997.
Presland, “Epithelial Structural Proteins of the Skin and Oral Cavity: Function in Health and Disease,”Crit. Rev. Oral. Biol. Med., 11(4):383-408, 2000.
Redl et al., “Procalcitonin Release Patterns in a Baboon Model of Trauma and Sepsis: Relationship to Cytokines and Neopterin,”Crit. Care Med., 28(11):3659-3663, 2000.
Redl and Schlag, “Non-Human Primate Models of Sepsis,”Sepsis, 2:243-253, 1998.
Reinhart et al., “Sepsis Und Spetischer Schcok,”Intensivmedizin, 756-760, 2001.
Shariat-Madar and Schmaier, “Kininogen-Cytokeratin 1 Interactions in Endothelial Cell Biology,”Trends Cardiovasc. Med., 9(8):238-244, 1999.
Shariat-Madar et al., “Mapping Binding Domains of Kininogens on Endothelial Cell Cytokeratin 1,”J. Biol. Chem., 274(11):7137-7145, 1999.
Stieber, “34.10 CYFRA 21-1 (Cytokeratin-19-Fragmente),”Thomas Labor Diagnose, 987-992.
Stigbrand, “The Versatility of Cytokeratins as Tumor Markers,”Tumor Biol., 22:1-3, 2001.
Wiedenmann et al., “Cytokeratin Fragments in Serum Possible New Markers for the Follow-up of Patients with Inflammatory Liver Disease,”Gastroenterology, 96(5);A673, 1989.
International Search Report for PCT/EP 02/06473, mailed Nov. 6, 2002.
Bergmann Andreas
Struck Joachim
Ühlein Monika
Desai Anand
Dias Kathy Smith
Heslin Rothenberg Farley & & Mesiti P.C.
Wax Robert A.
LandOfFree
Use of soluble cytokeratin-1-fragments in diagnostics and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of soluble cytokeratin-1-fragments in diagnostics and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of soluble cytokeratin-1-fragments in diagnostics and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638904